Observational Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1552-1561
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1552
Table 1 Clinical features of five patients
Case
Age
Sex
Trigger to be found
PS
Grade
Distal intestinal lesion
Extra-duodenal lesion
Initial stage
FLIPI
165FScreening EGD01Jejunum(-)ILow
263FFollow-up for GERD01JejunumBone marrowIVInt
340MScreening EGD01Not testedBone marrow, mesenteric LNIVLow
442MScreening EGD01(-)(-)ILow
542MScreening EGD01Not tested(-)ILow
Table 2 Treatment and outcome of 5 patients
Case
Treatment motive
Initial treatment
Effect
Rituximab maintenance
Relapse lesion/re-Stage (from the end of treatment)
2nd treatment
Outcome (from the 1st onset)
1Previously followed doctor’s judgmentRTX1st CR(-)Duodenum + cervical LN/Stage IV (1 yr and 3 mo)R-THP-COP2nd CR (18 years)
2In stage IVR-CVP + R-F1st CR(+)Colon + mesenteric LN/Stage II1 (1 yr and 7 mo)Watch2nd CR (12 yr)
3In stage IVR-CHOP1st CR(+)(-)-1st CR (13 yr)
4Patient’s requestRadiation + RTX1st CR(-)(-)-1st CR (16 yr)
5Patient’s requestCHOP/RTX/radiation1st CR(-)Lung + systemic LN/Stage IV (13 yr)B-R/R-BAC/CHOEP/ONTZDeath due to primary disease (21 yr)